The 250 delegates at the recent Human Resource Management Association of Jamaica (HRMAJ) 44th annual leadership conference agreed that members had a significant role to play in Jamaica realising its goals under Vision 2030. This included developing a thriving work place, so as to achieve each employee’s fullest potential and a secure, just and cohesive society, in order for the Jamaican economy to be prosperous. The conference, held on November 14 and 15 at the AC Marriott Hotel in Kingston, focused on helping leaders and human resource management practitioners to better understand that their contribution is critical to organisational and national development. The two-day conference was under the theme “HR Revolution: Navigating The Future...2030 and Beyond.” Among the key topics covered were the transformative role of artificial intelligence (AI); diversity, equity and inclusion (DEI); work-life integration; work place flexibility, as well human-centric and adaptive leadership in navigating current and future complexities of a rapidly evolving work force. Attendees benefitted from future-focused discussions on emerging human resource trends and practices; expected challenges; strategies and opportunities to review real-world examples and success stories from local and international organisations. “HRMAJ is committed to elevating the ‘people profession’, which has expanded beyond what we typically once knew as the HR functions,” said HRMAJ President Dr Cassida Jones Johnson, Independent Executive Consultant with over 20 years’ experience in strategic human resource, talent management, people engagement and executive coaching. “With other roles emerging in preparation for the future workplace, which has been changing in definition, the significance of upskilling and reskilling in the field in preparation for the role and impact of AI provide opportunities to transition administrative functions and areas such as culture, engagement and human-centric leadership at the forefront of all organisations,” she continued. “In fact, our 44th conference has raised the anchor for navigating the seas ahead, with opportunities to collaborate with other associations across the region and in developed countries.” Conference Chair Dr Lois Parkes, Leadership Development Institutional Specialist for the Caribbean Centre for Development Administration, noted: “Conference 44 was a huge success, as it created the platform for deep discussions on critical human resource and leadership policy challenges affecting both the private and public sectors. Going forward, HRMAJ will continue to provide an avenue for further dialogue, policy guidance and capacity building to empower work organisations to address these challenges head on.” To encourage work-life balance, the delegates were treated to representations of Jamaica’s rich cultural heritage of film and comedy through the showing of the six winning films of the Jamaica Cultural Development Commission (JCDC) Short Film Competition 2024, the Laugh Lab and open mic with comedians Elias Fennell and Christopher ‘Johnny’ Daley. There was also a wellness component by fitness advocate Shani McGraham-Shirley, who conducted exercise sessions. The conference was supported by such sponsors as Caribbeanjobs.com; Securys (Jamaica) Limited; HEART/NSTA Trust; Management Institute for National Development (MIND); National Housing Trust (NHT) and John Galt Insurance Brokers Limited. Exhibitors included: Dale Carnegie Training; Jamaica Stock Exchange e-Campus; Bioregeneration Integrated Medical Centre; Allied Insurance Brokers & GK Mutual Funds; Mona School of Business; Gift Tech Limited; University of Technology Jamaica (UTECH), Return on Investment Consulting (ROIC) Limited; Orbit360 & Roar Unleashed and Caribbean HR Solutions. Through advocacy, policy guidance and world-class training in many areas of human resource and leadership to build capacity, competencies and credibility for people professionals and emerging leaders, HRMAJ remains committed to promoting organisational growth, enhancing human capital development and increasing workforce productivity. The association may be reached through website www.hrmaj.org.fortune gems hack 。

The United States Postal Service states it is primed and ready to deliver exceptional service during the 2024 holiday rush thanks in large part to the investments and strategies identified in its 10-year Delivering for America plan. “Thanks to the substantial progress we have made under the Delivering for America plan, we are ready and confident to handle the holiday surge,” said USPS Chief Retail and Delivery Officer and Executive Vice President Dr. Joshua Colin. “Our ability to move packages and mail throughout our network has never been stronger. USPS continues to be the most affordable and reliable way to ship packages and mail this holiday season and year-round.” Because of the ongoing implementation of the Delivering for America strategic plan, 98% of the nation’s population currently receives their mail and packages in fewer than three days. The nation’s postal network is operating effectively without any major reported disruptions. “The United States Postal Service’s portfolio of shipping products makes holiday shipping easy,” said Steve Montieth, USPS chief customer and marketing officer and executive vice president. “Both USPS Ground Advantage and USPS Priority Mail are priced lower than competitors, meaning customers can save more this holiday season. So, ship early and enjoy your holiday season.” Key Investments Ahead of 2024 Peak Season Specifically, key Delivering for America investments in the Postal Service’s workforce, package processing, and delivery operations ahead of the 2024 peak holiday season include: – Using 83 revitalized sorting and delivery centers: In alignment with the Delivering for America plan, the postal service is revamping its network of nearly 19,000 delivery units, which are the final stop for mail and packages before they are delivered by letter carriers. These revitalized sorting and delivery centers have allowed USPS to expand its daily package processing capacity, increase its efficiency and deliver more value to its customers. – Implementing 506 new package sorting machines: These new machines are strategic investments in the local community’s postal infrastructure, enabling postal workers to sort and process packages of all sizes more quickly and reliably. Since the previous peak season, 158 new sorting machines have been installed across the nation. This is part of the organization’s $40 billion investment in new technology and facilities under the Delivering for America plan. – Increased daily processing capacity to approximately 60 million: An expanded daily processing capacity, stabilized workforce, improved operating precision, and well-planned transportation practices has allowed for packages to move through the postal network more quickly and helps eliminate the need for short-term annexes. – Moving more than 95% of volume via more reliable ground transportation: More precise operating and logistical strategies have positioned the postal service to handle the high mail and package volumes anticipated during the peak holiday season. USPS continues to transition more volume from expensive air transportation to its redesigned ground transportation network. Currently, nearly 95% of First-Class Mail and more than 95 percent of packages are moved through the improved, more reliable ground transportation system. – Hiring 7,500 seasonal employees: Because of its experienced and stable workforce, USPS anticipates the need for less seasonal employees this holiday season. – The initial release of the new next generation delivery vehicles: This holiday season will also mark the initial release of the brand-new BEV Next Generation Delivery Vehicles, which will be on select roads and routes this winter. Additionally, this holiday season, there will be more than 27,000 new vehicles on the road with more than 500 being battery-electric. USPS Makes Holiday Shipping Easy for Consumers In addition to key investments, USPS is simplifying the process and reducing customers' cost to ship packages this holiday season. – USPS Ground Advantage: This enhanced shipping solution provides a simple, reliable and more affordable way to ship packages this holiday season in just 2-5 business days across the contiguous United States. USPS Ground Advantage provides America’s businesses and the public with a compelling ground shipping option, using the Postal Service’s unparalleled last-mile delivery route system and improving the integrated mail and package postal logistics network. – The most affordable rates: Priority Mail is part of our package offering that provides a fast and affordable way to deliver mail to every address in the United States. During peak season, Priority Mail offers a price that is on average 35 percent lower than similar competitor services. Recommended Send-by Dates for Expected Delivery before Dec. 25 – For items shipped within the contiguous U.S., deadlines are Dec. 18 for USPDS Ground Advantage or First-Class Mail service, Dec. 19 for Priority Mail, and Dec. 21 for Priority Mail Express. – Shipping deadlines for Alaska and Hawaii are Dec. 16 for USPS Ground Advantage, Dec. 18 for First-Class Priority Mail, Dec. 19 for Priority Mail and Dec. 20 for Priority Mail Express. For deadlines on international and military mail, tips on preparing shipments, packaging guidelines, ordering free shipping supplies and information on local Post Office location hours, visit usps.com .

NEW YORK , Nov. 26, 2024 /PRNewswire/ -- Report with the AI impact on market trends - The global surgical robots market size is estimated to grow by USD 14.02 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 27.17% during the forecast period. High adoption due to convenience is driving market growth, with a trend towards high demand from developing countries. However, cost and affordability associated with surgical robots poses a challenge.Key market players include Accuray Inc., Asensus Surgical US Inc., CMR Surgical Ltd., Intuitive Surgical Inc., Johnson and Johnson Services Inc., Medtronic Plc, Microbot Medical Inc., Momentis Innovative Surgery Ltd., Neocis Inc., Novus International Inc., OMNI Orthopaedics Inc., Renishaw Plc, Siemens AG, Smith and Nephew plc, Stryker Corp., Titan Medical Inc, United Orthopedic Corp., Virtual Incision, and Zimmer Biomet Holdings Inc.. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF Market Driver Surgical robots are revolutionizing the healthcare industry with their precision and minimally invasive capabilities. The market for surgical robots is growing, particularly in the outpatient and ambulatory surgery segments. HD cameras and automated instruments are key trends in this market, enabling surgeons to perform complex procedures with greater accuracy. The urological surgery segment is a major contributor, with a high demand for robotic assistance in procedures like prostatectomies and nephrectomies. General surgery, gynaecological surgery, neurosurgery, and oncology segments also show strong growth. Surgical robots are increasingly being used in ambulatory surgery centers and clinics, reducing the need for inpatient facilities. Medicare coverage and the rising number of surgical errors have fueled the adoption of these systems. Orthopedic surgeries for bone degenerative diseases like arthritis, osteoporosis, hip replacement surgeries, and knee replacement surgeries are common applications. Minimally invasive techniques are preferred due to faster recovery times and smaller scars. Surgical robotic systems are being used for a wide range of procedures, from cardiac surgery and cataract surgery to neurosurgeries and cancer treatment procedures. The market for instruments and accessories is also growing. The future of surgical robots lies in miniaturization and the ability to perform complex procedures with greater precision. Healthcare providers are investing in these systems to improve patient outcomes and reduce costs. Surgical robotics technology is experiencing significant growth in demand, particularly in developing countries. Healthcare systems in these regions aim to improve patient outcomes and enhance healthcare services. Developing countries, such as India and Brazil , often face a shortage of specialized surgeons. Surgical robots offer a solution by providing a platform for training and skill development. These systems include simulation capabilities, enabling surgeons to practice complex procedures in a controlled environment, thereby improving their proficiency and delivering better patient care. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges Surgical robots have revolutionized the healthcare industry, particularly in areas like urological, general, and gynaecological surgeries. However, challenges persist. HD cameras and miniaturization are key advancements, but costs remain high. Outpatient surgery and ambulatory surgery centers are growing, but Medicare reimbursement policies need clarification. Surgical errors are a concern, especially in complex procedures like neurosurgeries and oncology. The U.S. Market for surgical robots is expanding, driven by orthopedic surgeries for bone degenerative diseases like arthritis and osteoporosis. Replacement rates for hip and knee surgeries are increasing, with primary hip replacement and primary knee replacement being common procedures. Physicians and surgeons are adopting automated instruments for minimally invasive surgeries, benefiting adults with chronic diseases like cancer. Instruments and accessories for soft tissues and bones are in demand, as are surgical robotic systems for laparoscopy and general surgical procedures. The outpatient segment, including ambulatory surgical centers and surgical centers, is growing, shifting focus from inpatient facilities. Traditional surgery techniques face competition from minimally invasive ones, with brain surgeries and neurological disorders being key areas of development. Surgical intervention for cardiac surgery, cataract surgery, hernia repair, cholecystectomy, adrenalectomy, small bowel resection, and rectal prolapse are all potential applications. The future of surgical robots lies in continuous innovation and collaboration between healthcare providers and technology companies. Surgical robots have become a notable trend in healthcare, offering enhanced capabilities for surgical procedures. However, the financial aspect of acquiring and maintaining these robotic systems is a substantial challenge in the market. The initial investment for purchasing and installing surgical robots, as well as ongoing expenses for staff training, maintenance, and instrument sterilization, can be substantial. Regular maintenance is crucial for optimal performance and longevity, involving inspections, software updates, and equipment calibration, which may result in additional costs, such as service contracts or technician fees. Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This surgical robots market report extensively covers market segmentation by 1.1 General and laparoscopy surgery 1.2 Gynecological surgery 1.3 Orthopedic surgery 1.4 Neurosurgery 1.5 Urology and others 2.1 Hospitals 2.2 Ambulatory service centers 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 General and laparoscopy surgery- Surgical robots have significantly increased in popularity for both general and laparoscopic surgeries due to their numerous advantages. According to the World Health Organization, approximately 200-400 million surgical procedures are performed globally each year. These robots offer surgeons enhanced precision and visualization, enabling them to perform complex procedures with minimal scarring, shorter hospital stays, and quicker recovery times. Equipped with advanced instruments like articulated robotic arms and high-definition cameras, surgical robots provide surgeons with a magnified 3D view of the surgery site and improved instrument maneuverability. Furthermore, integration with technologies like augmented reality offers surgeons a more detailed understanding of patient-specific anatomical details. The adoption of surgical robots is projected to boost the growth of the general and laparoscopic surgery market during the forecast period. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis Surgical robots are advanced medical devices that enable HD cameras and automated instruments to perform precise and minimally invasive surgeries. These robots are increasingly being used in outpatient surgery and ambulatory surgery centers for various procedures, including orthopedic surgeries for bone degenerative diseases like arthritis, osteoporosis, hip replacement, and knee replacement surgeries for joints affected by osteoarthritis. Chronic diseases such as cardiac conditions, cancer, and cataracts are also treated with surgical intervention using surgical robots. The use of surgical robots reduces surgical errors, enhances precision, and improves patient outcomes. Medicare and other healthcare providers are recognizing the benefits of these technologies, leading to increased adoption. Instruments and accessories for soft tissues and bones are also available for these robots to expand their capabilities. Market Research Overview Surgical robots are advanced medical devices that enable doctors to perform complex surgeries with greater precision and control. These robots, equipped with HD cameras and automated instruments, are increasingly being used in outpatient and ambulatory surgery settings, including ambulatory surgery centers and clinics. Medicare and other healthcare providers are recognizing the benefits of surgical robots, such as reduced surgical errors, shorter hospital stays, and faster recovery times. The urological surgery segment is a significant market for surgical robots, with applications including prostatectomies, nephrectomies, and cystectomies. General surgery, gynaecological surgery, neurosurgery, and oncology are other major application areas. Surgical robots are used in various types of surgeries, including orthopedic surgeries for bone degenerative diseases like arthritis and osteoporosis, hip replacement surgeries, and knee replacement surgeries. Surgical robots are also used in minimally invasive procedures for soft tissues and abnormal structures, such as hernia repair, cholecystectomy, adrenalectomy, and small bowel resection. The market for surgical robots is expected to grow significantly due to the increasing rate of primary hip replacement and primary knee replacement surgeries, as well as the growing number of chronic diseases affecting adults, such as cardiac conditions and cancer. The miniaturization of surgical robotic systems is also driving growth in the market, as these systems can be used in outpatient segment surgical centers and healthcare facilities, reducing the need for inpatient facilities. Traditional surgery techniques are being replaced by minimally invasive techniques, such as laparoscopy, which offer less scarring and faster recovery times. The neurology segment, including neurosurgeries for neurological disorders, is also a growing market for surgical robots. The use of surgical robots in cancer treatment procedures, such as brain surgeries, is expected to drive significant growth in the market. Instruments and accessories are also a significant part of the surgical robots market. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Application General And Laparoscopy Surgery Gynecological Surgery Orthopedic Surgery Neurosurgery Urology And Others End-user Hospitals Ambulatory Service Centers Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE Technavio

Application Threat Modeling Myths Debunked

Matías Tarnopolsky to become New York Philharmonic CEO, teaming with Gustavo DudamelGame show host Wink Martindale is 91. Singer Freddy “Boom Boom” Cannon is 88. Actor-producer-director Max Baer Junior (“The Beverly Hillbillies”) is 87. Actor Gemma Jones is 82. Bassist Bob Mosley of Moby Grape is 82. Singer-bassist Chris Hillman of The Byrds and of the Flying Burrito Brothers is 80. Singer Southside Johnny Lyon of Southside Johnny and the Asbury Jukes is 76. Actor Jeff Bridges is 75. Actor Patricia Wettig is 73. Drummer Brian Prout of Diamond Rio is 69. Jazz singer Cassandra Wilson is 69. Bassist Bob Griffin of The BoDeans is 65. Singer Vinnie Dombroski of Sponge is 62. Actor Marisa Tomei is 60. Comedian Fred Armisen (“Portlandia,” “Saturday Night Live”) is 58. Rapper Jay-Z is 55. Actor Kevin Sussman (“Ugly Betty”) is 54. Model Tyra Banks is 51. . — Associated Press Get local news delivered to your inbox!( MENAFN - Investor Brand Network) SenesTech (NASDAQ:SNES) reported a 51% increase in revenue for the first nine months of 2024, totaling $1.4 million, driven by strong sales of its Evolve Rat and Evolve Mouse products. Gross margins improved to 65% in Q3 2024, up from 49% in the same quarter last year, due to enhanced manufacturing efficiency. The company's operating expenses decreased by 12%, and its adjusted EBITDA loss was the smallest in its history, reducing cash burn by 21%. Evolve Rat, launched in early 2024, now accounts for 52% of Q3 revenue, and the company has expanded sales through e-commerce platforms like Amazon and Walmart. Additionally, SenesTech is expanding into international markets, securing significant orders from distributors in Hong Kong and the Netherlands. The company is also exploring municipal opportunities, including a rat contraception pilot program in New York City. To view the full press release, visit About SenesTech Inc. SenesTech is committed to improving the health of the world by humanely managing animal-pest populations through its expertise in fertility control. Senestech is the inventor of Evolve(TM) Rat and Evolve(TM) Mouse, EPA-designated, minimum-risk contraceptives for rodents, which reflects the company's mission to provide products that are proactive, safe and sustainable. Evolve fits seamlessly into all integrated pest-management programs, significantly improving the overall goal of effective pest management. The company's strives for clean cities, efficient businesses and happy households - with a product designed to be humane, effective and sustainable. For more information about the company, please visit . NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company's newsroom at About TechMediaWire TechMediaWire (“TMW”) is a specialized communications platform with a focus on pioneering public and private companies driving the future of technology. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, TMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today's market, TMW brings its clients unparalleled recognition and brand awareness. TMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from TechMediaWire, text“TECH” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: /Disclaimer TechMediaWire Los Angeles, CA 310.299.1717 Office [email protected] TechMediaWire is powered by IBN MENAFN02122024000224011066ID1108948966 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

NonePutin Says Russia Fired ‘Hypersonic’ Ballistic Missile At Ukraine, Warns West!

According to DelveInsight's analysis, the market for Down syndrome is anticipated to increase during the forecast period (2024–2034), owing to the launch of emerging therapies such as AEF0217, ACI-24.060, LEUCETTINIB-21, BUNTANETAP, and others and healthcare spending globally. LAS VEGAS , Nov. 26, 2024 /PRNewswire/ -- DelveInsight's Down's Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Down's syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ) and the United Kingdom , and Japan ]. Key Takeaways from the Down's Syndrome Market Report According to DelveInsight's analysis, the market size for Down's syndrome was found to be USD 241 million in the US in 2023. In 2023, the United States accounted for nearly 220K prevalent cases of Down's syndrome. The types of Down's syndrome include Trisomy 21, Robertsonian translocation, and Mosaicism. In 2023, among all types, Trisomy 21 accounted for the highest number of prevalent cases in the 7MM. Leading Down's syndrome companies such as AELIS FARMA, AC IMMUNE, PERHA PHARMACEUTICALS, ANNOVIS BIO, APHIOS THERAPEUTICS, and others are developing novel Down's syndrome drugs that can be available in the Down's syndrome market in the coming years. The promising Down's syndrome therapies in the pipeline include AEF0217, ACI-24.060, LEUCETTINIB-21, BUNTANETAP, APH-1104, and others. Discover which therapies are expected to grab the major Down's syndrome market share @ Down's Syndrome Market Report Down's Syndrome Overview Down's syndrome, also known as trisomy 21, is a genetic disorder caused by the presence of an extra copy of chromosome 21. This chromosomal anomaly disrupts normal development, resulting in a range of physical and cognitive differences. The condition is primarily caused by random genetic mutations during the formation of reproductive cells or early embryonic development, though advanced maternal age increases the likelihood of having a child with Down's syndrome. People with Down's syndrome typically exhibit distinct facial features, such as a flattened face, almond-shaped eyes that slant upward, and a small nose. Other common symptoms include developmental delays, intellectual disabilities, and a variety of health issues like heart defects, respiratory and hearing problems, and a higher susceptibility to infections. Despite these challenges, many individuals with Down's syndrome lead fulfilling lives with appropriate support. Diagnosis of Down's syndrome can occur prenatally through screening and diagnostic tests, such as blood tests and ultrasounds in the first and second trimesters, or through more definitive tests like chorionic villus sampling (CVS) and amniocentesis. Postnatal diagnosis is typically confirmed by a physical examination and a karyotype analysis to identify the extra chromosome. Early diagnosis and intervention can help address developmental needs and improve the quality of life for individuals with Down's syndrome. Down's Syndrome Epidemiology Segmentation The Down's syndrome epidemiology section provides insights into the historical and current Down's syndrome patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The Down's syndrome market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Diagnosed Prevalent Cases of Down's Syndrome Gender-specific Diagnosed Prevalent Cases of Down's Syndrome Type-specific Diagnosed Prevalent Cases of Down's Syndrome Age-specific Diagnosed Prevalent Cases of Down's Syndrome Diagnosed Cases of Down's Syndrome by Clinical Manifestations Down's Syndrome Treatment Market There is no single treatment for Down's syndrome; instead, care plans are customized to address each person's unique physical and intellectual needs, emphasizing their strengths and accommodating their limitations. For some individuals, immediate surgery may be needed after birth to correct heart defects or long-term dietary modifications may be required for digestive concerns. Common interventions include assistive devices such as hearing aids, mobility aids, and adaptive technology to support learning and daily tasks. People with Down's syndrome often face an earlier and more pronounced cognitive decline than the general population. Treatments for Down syndrome-associated dementia (DSAD) may include medications like rivastigmine, galantamine, memantine, and donepezil, which inhibit acetylcholine breakdown, providing notable benefits. Seizure management for those with Down syndrome may involve anticonvulsants like carbamazepine and phenytoin, although these can exacerbate other Down syndrome-related issues. Respiratory problems are also common due to immune deficiencies and respiratory tract abnormalities, often requiring antibiotics or inhaled bronchodilators for effective management. Along with pharmacological treatments, non-pharmacological therapies such as physical, speech, occupational, and behavioral therapies play a vital role in the early development of children with Down syndrome, promoting independence and productivity. Physical therapy aims to improve motor skills, build muscle strength, and enhance posture and balance, laying the groundwork for key abilities. Speech-language therapy focuses on boosting communication skills and addressing physical challenges like low muscle tone to avoid long-term complications. Occupational therapy adapts daily tasks to suit the individual's abilities, teaching crucial skills such as eating, dressing, writing, and using a computer. Emotional and behavioral therapies tackle challenges like frustration from communication barriers, compulsive behaviors, and ADHD by identifying triggers and creating strategies to foster positive behaviors and reduce undesirable ones. To know more about Down's syndrome treatment guidelines, visit @ Down's Syndrome Management Down's Syndrome Pipeline Therapies and Key Companies AEF0217: AELIS FARMA ACI-24.060: AC IMMUNE LEUCETTINIB-21: PERHA PHARMACEUTICALS BUNTANETAP: ANNOVIS BIO APH-1104: APHIOS THERAPEUTICS Discover more about Down's syndrome drugs in development @ Down's Syndrome Clinical Trials Down's Syndrome Market Dynamics The Down's syndrome market dynamics are expected to change in the coming years. The prevalence of Down syndrome has increased with the rise in lifespan over the past three decades. This, along with the combination of several neurological features in Down syndrome patients—such as language impairment, cognition, learning, and memory—has sparked intense neurodevelopmental research. Studies in this area hold promise for improving clinical care and quality of life for individuals with Down syndrome and their families, as well as for assessing ways to enhance communication between parents and children. A thorough understanding of the factors affecting pharmacotherapy in Down syndrome could significantly contribute to better clinical outcomes for these individuals. Furthermore, potential therapies are being investigated for the treatment of Down's syndrome, and it is safe to predict that the treatment space will significantly impact the Down's syndrome market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Down's syndrome market in the 7MM. However, several factors may impede the growth of the Down's syndrome market. Down syndrome presents unique challenges in clinical treatment, as there is currently no medical cure or approved products available in the market, complicating the treatment process. This complexity is compounded by the lack of appropriate, validated scales to measure progress or side effects in participants with learning disabilities, making it difficult to gauge treatment impact effectively. Furthermore, recruiting participants and their families is challenging, adding to the difficulties in conducting research. Down syndrome is also associated with numerous health problems and high healthcare costs , and individuals may require more intensive monitoring for adverse effects, adherence, and treatment efficacy when managing medications. Conducting clinical studies on the efficacy of psychotropic medications in individuals with Down syndrome is particularly challenging due to the unique language and communication characteristics of this population. Moreover, Down's syndrome treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, Down's syndrome market growth may be offset by failures and discontinuation of emerging therapies , unaffordable pricing , market access and reimbursement issues , and a shortage of healthcare specialists . In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact Down's syndrome market growth. Down's Syndrome Market Report Metrics Details Study Period 2020–2034 Coverage 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Down's Syndrome Market CAGR 3.81 % Down's Syndrome Market Size in the US in 2023 USD 241 Million Key Down's Syndrome Companies AELIS FARMA, AC IMMUNE, PERHA PHARMACEUTICALS, ANNOVIS BIO, APHIOS THERAPEUTICS, and others Key Pipeline Down's Syndrome Therapies AEF0217, ACI-24.060, LEUCETTINIB-21, BUNTANETAP, APH-1104, and others Scope of the Down's Syndrome Market Report Therapeutic Assessment: Down's Syndrome current marketed and emerging therapies Down's Syndrome Market Dynamics: Key Market Forecast Assumptions of Emerging Down's Syndrome Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Down's Syndrome Market Access and Reimbursement Download the report to understand which factors are driving Down's syndrome market trends @ Down's Syndrome Market Trends Table of Contents 1 KEY INSIGHTS 2 REPORT INTRODUCTION 3 EXECUTIVE SUMMARY OF DOWN'S SYNDROME 4 DOWN'S SYNDROME MARKET OVERVIEW AT A GLANCE 4.1 MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF DOWN'S SYNDROME IN 2020 IN THE 7MM 4.2 MARKET SHARE BY THERAPIES (%) DISTRIBUTION OF DOWN'S SYNDROME IN 2034 IN THE 7MM 5 KEY EVENTS 6 EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY 7 DOWN'S SYNDROME: DISEASE BACKGROUND AND OVERVIEW 7.1 INTRODUCTION 7.2 ETIOLOGY 7.3 TYPES OF DOWN'S SYNDROME 7.3.1 Trisomy 21 7.3.2 Translocation Down's syndrome 7.3.3 Mosaic Down's syndrome 7.4 CAUSES AND RISK FACTORS 7.5 COMPLICATIONS 7.6 OTHER HEALTH PROBLEMS 7.7 DIAGNOSIS 7.7.1 Screening Tests 7.7.2 Diagnostic Tests 7.8 TREATMENTS 7.8.1 Early Intervention and Educational Therapy 7.8.2 Treatment Therapies 7.8.3 Drugs and Supplements 7.8.4 Assistive Devices 8 CASE REPORTS 8.1 CASE STUDY: AN IPP TEAM HELPS 6-YEAR WITH DOWN'S SYNDROME IMPROVE COMMUNICATION SKILLS 9 EPIDEMIOLOGY AND PATIENT POPULATION 9.1 KEY FINDINGS 9.2 ASSUMPTIONS AND RATIONALE 9.3 TOTAL PREVALENT CASES OF DOWN'S SYNDROME IN THE 7MM 9.4 TYPE-SPECIFIC CASES OF DOWN'S SYNDROME IN THE 7MM 9.5 GENDER-SPECIFIC CASES OF DOWN'S SYNDROME IN THE 7MM 9.6 PREVALENT CASES OF DOWN'S SYNDROME BY CLINICAL MANIFESTATIONS IN THE 7MM 9.7 PREVALENT CASES OF DOWN'S SYNDROME BY AGE IN THE 7MM 9.8 THE UNITED STATES 9.8.1 Total Prevalent Cases of Down's Syndrome in the US 9.8.2 Type-specific Cases of Down's Syndrome in the US 9.8.3 Gender-specific Cases of Down's Syndrome in the US 9.8.4 Prevalent cases of Down's Syndrome by clinical manifestations in the US 9.8.5 Prevalent cases of Down's Syndrome by Age in the US 9.9 EU4 AND THE UK 9.9.1 Total Prevalent Cases of Down's syndrome in EU4 and the UK 9.9.2 Type-specific Cases of Down's syndrome in EU4 and the UK 9.9.3 Gender-specific Cases of Down's syndrome in EU4 and the UK 9.9.4 Prevalent cases of Down's syndrome by clinical manifestations in EU4 and the UK 9.9.5 Prevalent cases of Down's syndrome by Age in EU4 and the UK 9.10 JAPAN 9.10.1 Total Prevalent Cases of Down's syndrome in Japan 9.10.2 Type-specific Cases of Down's syndrome in Japan 9.10.3 Gender-specific Cases of Down's syndrome in Japan 9.10.4 Prevalent cases of Down's syndrome by clinical manifestations in Japan 9.10.5 Prevalent cases of Down's syndrome by Age in Japan 10 PATIENT JOURNEY 11 EMERGING DRUGS 11.1 KEY COMPETITORS 11.2 AEF0217: AELIS FARMA 11.2.1 Product Description 11.2.2 Other Developmental Activities 11.2.3 Clinical Development 11.2.3.1 Clinical Trials Information 11.2.4 Safety and Efficacy 11.3 ACI-24.060: AC IMMUNE 11.3.1 Product Description 11.3.2 Clinical Development 11.3.2.1 Clinical Trials Information 11.3.3 Safety and Efficacy 11.4 LEUCETTINIB-21: PERHA PHARMACEUTICALS 11.4.1 Product Description 11.4.2 Clinical Development 11.4.2.1 Clinical Trials Information 11.4.3 Other Developmental Activities 11.4.4 Safety and Efficacy 11.5 BUNTANETAP: ANNOVIS BIO 11.5.1 Product Description 11.5.2 Other Developmental Activities 11.5.3 Safety and Efficacy 11.6 APH-1104: APHIOS THERAPEUTICS 11.6.1 Product Description 11.6.2 Other Developmental Activities 12 DOWN'S SYNDROME: MARKET ANALYSIS 12.1 KEY FINDINGS 12.2 MARKET OUTLOOK 12.3 CONJOINT ANALYSIS 12.4 KEY MARKET FORECAST ASSUMPTIONS 12.5 TOTAL MARKET SIZE OF DOWN'S SYNDROME IN THE 7MM 12.6 UNITED STATES MARKET SIZE 12.6.1 Total Market Size of Down's Syndrome in the United States 12.6.2 Market Size of Down's Syndrome by Therapies in the United States 12.7 EU4 AND THE UK MARKET SIZE 12.7.1 Total Market Size of Down's Syndrome in EU4 and the UK 12.7.2 Market Size of Down's Syndrome by Therapies in EU4 and the UK 12.8 JAPAN MARKET SIZE 12.8.1 Total Market Size of Down's Syndrome in Japan 12.8.2 Market Size of Down's Syndrome by Therapies in Japan 13 UNMET NEEDS 14 SWOT ANALYSIS 15 MARKET ACCESS AND REIMBURSEMENT 15.1 UNITED STATES 15.1.1 Centre for Medicare & Medicaid Services (CMS) 15.2 EU4 AND THE UK 15.2.1 Germany 15.2.2 France 15.2.3 Italy 15.2.4 Spain 15.2.5 United Kingdom 15.3 JAPAN 15.3.1 MHLW 16 APPENDIX 16.1 BIBLIOGRAPHY 16.2 REPORT METHODOLOGY 17 DELVEINSIGHT CAPABILITIES 18 DISCLAIMER 19 ABOUT DELVEINSIGHT Related Reports Down's Syndrome Epidemiology Forecast Down's Syndrome Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Down's syndrome epidemiology trends. Down's Syndrome Pipeline Down's Syndrome Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Down's syndrome companies, including Alzheon, Inc, Connecta Therapeutics, among others. Alport Syndrome Market Alport Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alport syndrome companies, including Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec , among others. Alport Syndrome Pipeline Alport Syndrome Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alport syndrome companies, including Eloxx Pharmaceuticals, Inc., Chinook Therapeutic/Novartis, River 3 Renal Corp., Travere Therapeutics, Inc., Reata Pharmaceuticals, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpgAbandoned Puppy’s Life Saved Through Groundbreaking Augmented Reality Technology